IPCI.H Stock Overview
A pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Intellipharmaceutics International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.08 |
| 52 Week High | CA$0.13 |
| 52 Week Low | CA$0.06 |
| Beta | 0.49 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -15.79% |
| 33 Year Change | -61.90% |
| 5 Year Change | -74.19% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPCI.H | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | 0.7% |
| 1Y | -15.8% | -22.3% | 21.7% |
Return vs Industry: IPCI.H underperformed the Canadian Pharmaceuticals industry which returned 32.2% over the past year.
Return vs Market: IPCI.H underperformed the Canadian Market which returned 10.4% over the past year.
Price Volatility
| IPCI.H volatility | |
|---|---|
| IPCI.H Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: IPCI.H has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IPCI.H's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 11 | Isa Odidi | www.intellipharmaceutics.com |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
Intellipharmaceutics International Inc. Fundamentals Summary
| IPCI.H fundamental statistics | |
|---|---|
| Market cap | CA$2.65m |
| Earnings (TTM) | -CA$4.40m |
| Revenue (TTM) | CA$1.25m |
2.1x
P/S Ratio-0.6x
P/E RatioIs IPCI.H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCI.H income statement (TTM) | |
|---|---|
| Revenue | US$904.95k |
| Cost of Revenue | US$475.89k |
| Gross Profit | US$429.06k |
| Other Expenses | US$3.60m |
| Earnings | -US$3.17m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 47.41% |
| Net Profit Margin | -350.72% |
| Debt/Equity Ratio | -16.9% |
How did IPCI.H perform over the long term?
See historical performance and comparison